Literature DB >> 6349797

Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22.

G A Croghan, L D Papsidero, L A Valenzuela, T Nemoto, R Penetrante, T M Chu.   

Abstract

Murine monoclonal antibody F36/22 was derived by immunizing BALB/c mice with human breast cancer cells. This antibody reacts with an antigen located both on differentiated mammary ductal epithelia and on breast carcinomas, as examined by indirect immunoperoxidase techniques. Although the expression of this antigen correlated with estrogen receptor levels of breast tumors, antibody F36/22 did not directly react with estrophilin. In contrast to the expression of classical differentiation antigens, this antigen was found in a high percentage of poorly differentiated carcinomas of the breast. Staining intensities were similar for well- and poorly differentiated tumors; thus, antigen expression was not related to tumor grade. Intratumoral heterogeneity of antigen expression was observed in the majority of tumors. Since a subset (64 of 80) of the breast carcinomas examined have expressed the antigen, McAb 36/22 was of use for the immunological subclassification of tumors which were indistinguishable by conventional histopathological staining techniques. The antigen was also present on other adenocarcinomas (ovary, colon, stomach, pancreas, and prostate); however, these tumors usually exhibited reduced staining intensity compared with that observed in breast cancer. The normal counterpart tissues at these histotypes contained no detectable levels of the antigen, and increased expression of the antigen was associated with tumorigenesis at these sites. Tumors of mesenchymal origin and carcinomas other than adenocarcinomas exhibited undetectable levels of the antigen. Therefore, depending on the organ site, McAb F36/22 recognizes an epithelial and/or tumor-associated antigen.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6349797

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Characterization of cell surface antigens expressed in the HMA-1 breast cancer cell line.

Authors:  N Ohuchi; Y Harada; T Masuko; S Matano; S Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

2.  Immunocytochemical distribution of a breast carcinoma associated glycoprotein identified by monoclonal antibodies.

Authors:  R Mesa-Tejada; R B Palakodety; J A Leon; A O Khatcherian; C J Greaton
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

3.  Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancer.

Authors:  M B Garcia; M A Blankenstein; E van der Wall; J W Nortier; J H Schornagel; J H Thijssen
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

4.  Human tumor and normal tissue reactivity of the anti-(breast cancer) monoclonal antibody BA-Br-3 and its similarity to the anti-(epithelial membrane antigen) monoclonal antibody E29.

Authors:  S K Liao; R E Flahart; B Kimbro; L Horton; R K Oldham; J Hilgers; R van der Gaag
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Monoclonal antibodies against antigens on breast cancer cells.

Authors:  C Stähli; B Takacs; V Miggiano; T Staehelin; H Carmann
Journal:  Experientia       Date:  1985-11-15

6.  Experimental tumoricidal effects of monoclonal antibody against solid breast tumors.

Authors:  P M Capone; L D Papsidero; G A Croghan; T M Chu
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

7.  Immunotherapy in a spontaneously developed murine mammary carcinoma with syngeneic monoclonal antibody.

Authors:  P M Capone; N Kadohama; T M Chu
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  The immunohistochemical reactivity of a new anti-epithelial monoclonal antibody (MAb b-12) against breast carcinoma and other normal and neoplastic human tissues.

Authors:  H R Zenklusen; C Stähli; F Gudat; J von Overbeck; J Rolink; P U Heitz
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

9.  Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients.

Authors:  J Lundy; A Thor; R Maenza; J Schlom; F Forouhar; M Testa; D Kufe
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

10.  Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.

Authors:  D F Hayes; H Sekine; T Ohno; M Abe; K Keefe; D W Kufe
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.